| 0.6275 -0.03 (-4.49%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.83 | 1-year : | 0.99 |
| Resists | First : | 0.71 | Second : | 0.85 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.5 | Second : | 0.41 |
| MAs | MA(5) : | 0.64 |
MA(20) : | 0.66 |
| MA(100) : | 0.56  |
MA(250) : | 0.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 41.1 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 1.75 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MNPR ] has closed above bottom band by 33.5%. Bollinger Bands are 30.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.66 |
| Low: | 0.61 - 0.62 | 0.62 - 0.62 |
| Close: | 0.62 - 0.63 | 0.63 - 0.63 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Thu, 18 Apr 2024
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging ... - GlobeNewswire
Tue, 16 Apr 2024
Monopar Therapeutics Advances Radiopharmaceuticals with New Patent - TipRanks.com - TipRanks
Tue, 16 Apr 2024
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings - GlobeNewswire
Tue, 16 Apr 2024
Monopar files patent protecting its MNPR-101 radiopharma optimization findings - Seeking Alpha
Thu, 04 Apr 2024
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Thu, 28 Mar 2024
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 52.3 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 171 (K) |
| Shares Short P.Month | 849 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53.7 % |
| Return on Equity (ttm) | -107.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | 1.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|